1. Could you elaborate on Cordlife’s business segments and each of its focus?

Established in May 2001, Cordlife Group is dedicated to safeguarding the well-being of mother and child. The group has been listed on the Mainboard of the Singapore Exchange since 2012. We are a pioneer in private cord blood banking and own the largest network of cord blood banks in Asia, with full stem cell banking facilities in six key markets — Singapore, Hong Kong, Indonesia, India, Malaysia, and the Philippines. All our facilities are accredited by AABB (formerly known as American Association of Blood Banks), with several also accredited by other leading standards organisations, such as Foundation for the Accreditation of Cellular Therapy (FACT) and College of American Pathologists (CAP).

Beyond cord blood, cord lining and cord tissue banking, we have extended our cryopreservation expertise to expanded stem cells in the Philippines and lenticules in Singapore, offering a comprehensive suite of diagnostics services for families including non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening and family genetic screening services.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook